Compare GABC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | INBX |
|---|---|---|
| Founded | 1910 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 1995 | 2024 |
| Metric | GABC | INBX |
|---|---|---|
| Price | $49.77 | $106.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $47.67 | ★ $150.00 |
| AVG Volume (30 Days) | 94.6K | ★ 328.0K |
| Earning Date | 04-27-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | ★ 8.13 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $487,401,000.00 | $1,300,000.00 |
| Revenue This Year | $16.78 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $26.18 | ★ N/A |
| Revenue Growth | 37.80 | ★ 550.00 |
| 52 Week Low | $37.19 | $26.19 |
| 52 Week High | $52.23 | $155.29 |
| Indicator | GABC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 51.72 |
| Support Level | $48.85 | $70.23 |
| Resistance Level | $51.97 | $131.01 |
| Average True Range (ATR) | 0.80 | 9.82 |
| MACD | -0.05 | -2.00 |
| Stochastic Oscillator | 69.15 | 44.50 |
German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.